BridgeBio Pharma (BBIO) Invested Capital (2019 - 2025)
Historic Invested Capital for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $74.3 million.
- BridgeBio Pharma's Invested Capital rose 10609.23% to $74.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.3 million, marking a year-over-year increase of 10609.23%. This contributed to the annual value of -$729.0 million for FY2024, which is 4616.74% up from last year.
- According to the latest figures from Q3 2025, BridgeBio Pharma's Invested Capital is $74.3 million, which was up 10609.23% from -$1.8 billion recorded in Q2 2025.
- Over the past 5 years, BridgeBio Pharma's Invested Capital peaked at $358.1 million during Q1 2021, and registered a low of -$1.8 billion during Q2 2025.
- Moreover, its 5-year median value for Invested Capital was -$1.1 billion (2024), whereas its average is -$904.1 million.
- In the last 5 years, BridgeBio Pharma's Invested Capital plummeted by 1312673.52% in 2022 and then soared by 10609.23% in 2025.
- BridgeBio Pharma's Invested Capital (Quarter) stood at -$867.0 million in 2021, then plummeted by 43.41% to -$1.2 billion in 2022, then dropped by 8.92% to -$1.4 billion in 2023, then skyrocketed by 46.17% to -$729.0 million in 2024, then skyrocketed by 110.19% to $74.3 million in 2025.
- Its Invested Capital was $74.3 million in Q3 2025, compared to -$1.8 billion in Q2 2025 and -$1.6 billion in Q1 2025.